Improving the lives of people suffering from mental illness and substance use disorders

What we do



Developing innovative medicines for patients, creating value for healthcare providers

Digital Therapeutics

Digital Therapeutics

Pioneering evidence-based therapies, delivering better access for users

Mental illness & substance use disorders

Mental illness & substance use disorders

Focusing on areas of great human suffering with wider societal implications

 5 minutes video - get to know us

Key News

APRIL 28, 2022
Interim Report Q1 - Promising start to 2022

APRIL 27, 2022
Orexo´s partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI - systemic sclerosis

Listed on Nasdaq Stockholm´s mainlist

Orexo is listed on Nasdaq Stockholm´s mainlist, Mid Cap, (ORX), and can be traded on the US market, via an ADR on OTCQX Market (ORXOY).

MODIA™ - our digital therapy for opioid dependence

  • to be used along with pharmaceuticals
  • 6 months treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. up to 400 patients

News Flow

Regulatory Press Releases

Orexo Social

28 June 2022

It’s always a good time to check that your #epinephrine #autoinjector is in date and that you, and your loved ones,…

21 June 2022

Economic disruptions due to COVID-19, such as job loss, led to a sharp decrease in #addiction treatment among peopl…

17 June 2022

🎥DISCOVER OUR STORY 💠Where have we come from? 💠How have we evolved? 💠What motivates us to do what we do? To lea

Financial Snapshot

Group net revenues

592  MSEK



-134 MSEK


US Pharma segment EBIT

296 MSEK


Cash position

434 MSEK

Q1 2022

1 Last Twelve Months, Q221-Q122, for more information about financial development Link